Medications That Can Cause Falsely Low IGF-1
Proton pump inhibitors (PPIs), H2-receptor antagonists, and antacids can decrease IGF-1 levels by reducing the bioavailability of oral octreotide, which may lead to falsely low IGF-1 measurements in patients being monitored for acromegaly. 1
Primary Medications Affecting IGF-1 Levels
Medications That Decrease Bioavailability of Acromegaly Treatments
- Proton pump inhibitors (PPIs)
- H2-receptor antagonists
- Antacids
These medications specifically interfere with oral octreotide absorption, requiring dose increases of oral octreotide capsules (OOCs) to maintain therapeutic IGF-1 levels 1. When patients are concurrently treated with these gastric acid-suppressing agents, the OOC dose likely needs to be increased because these drugs decrease OOC bioavailability.
Oral Estrogens
Oral estrogen antagonizes growth hormone actions and can lower IGF-1 into the normal range, even in patients with acromegaly who have mildly elevated IGF-1 levels 2. This effect is specific to oral estrogen administration and makes the liver less responsive to GH, resulting in lower IGF-1 levels 3. This is a critical consideration when interpreting IGF-1 results in women taking oral contraceptives or hormone replacement therapy.
Clinical Conditions That Lower IGF-1 (Not Medications, But Important Context)
While not medications per se, several clinical conditions can cause falsely low or genuinely suppressed IGF-1 levels that clinicians must exclude before interpreting results:
- Malnutrition and catabolic states 2, 4
- Poorly controlled diabetes mellitus 2, 3
- Hepatic failure 2, 3
- Renal failure 2, 3
- Hypothyroidism 3, 4
- Severe infection 3
Practical Monitoring Recommendations
When evaluating IGF-1 levels, clinicians should:
- Review all concurrent medications, particularly gastric acid suppressants and oral estrogens
- Exclude systemic illness including the conditions listed above
- Use the same assay for serial measurements due to significant interassay variability 2
- Consider retesting if results are discordant with clinical presentation, as biological variability and assay performance issues can cause spurious results 5
Important Caveats
- In patients with poorly controlled diabetes attributable to acromegaly, serum IGF-1 levels should be remeasured when glycemic control has improved 2
- The effect of oral estrogens is particularly relevant for women with mild IGF-1 elevations, where oral estrogen can normalize previously elevated levels 2
- For patients on oral octreotide therapy taking PPIs, H2-blockers, or antacids, dose adjustments of the octreotide are necessary rather than accepting falsely low IGF-1 readings 1